Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA newly added guidance list shows a final Clinical Pharmacology guidance dated 18 June 2026: Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug.
The guidance is a technical specifications document for industry. It says it is intended to help sponsors submit datasets from clinical studies that evaluate immunogenicity and its impact on a drug's pharmacokinetics, and to provide detailed information and specifications for those datasets.
The document identifies three dataset areas: Analysis Dataset for Immunogenicity Specimen, Analysis Dataset for Pharmacokinetic Concentrations and Subject-Level Analysis Dataset. It says variable names and metadata are based on current CDISC SDTM and ADaM standards where possible.
FDA also says guidance documents generally describe the agency's current thinking and should be viewed as recommendations unless specific regulatory or statutory requirements are cited. Sponsors are told to document omitted or added variables in Define.xml and the Analysis Data Reviewer Guide, and to contact the applicable review division for submission-specific questions.
Why It Matters
Immunogenicity can affect exposure and safety for therapeutic proteins and other drugs. More consistent datasets should make it easier for reviewers to trace anti-drug antibody findings into pharmacokinetic analyses, and easier for sponsors to build submission pipelines that anticipate FDA review expectations.
Sourcing note: Confirmed facts are the FDA listing, final-guidance status, guidance title and contents of the FDA PDF. The operational implications for sponsors and reviewers are editorial analysis; the guidance itself is nonbinding unless tied to separate legal requirements.
Why It Matters
The change is not a new treatment approval or efficacy finding. It matters because standardised trial datasets can reduce ambiguity in how immunogenicity and pharmacokinetic evidence is reviewed, especially in complex biologic-drug submissions.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAClinical TrialsImmunogenicityPharmacokinetics